Please try another search
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Name | Age | Since | Title |
---|---|---|---|
Toru Kimura | 64 | 2016 | Representative Director, President & CEO |
Yoshio Iteya | 68 | 2018 | Outside Audit & Supervisory Board Member |
Takashi Kutsunai | 66 | 2014 | Full-Time Audit & Supervisory Board Member |
Hisayoshi Kashima | - | 2014 | Full-Time Audit & Supervisory Board Member |
Saeko Arai | 60 | 2018 | Independent Outside Director |
Nobuhiro Endo | 71 | 2019 | Independent Outside Director |
Koji Fujimoto | 61 | 2022 | Independent Outside Director |
Mayumi Mochizuki | 70 | 2021 | Outside Audit & Supervisory Board Member |
Minoru Usui | 69 | 2021 | Independent Outside Director |
Daishiro Michimori | 68 | 2022 | Outside Audit & Supervisory Board Member |
Hiroshi Niinuma | 66 | 2024 | Director |
Motoyuki Sakai | 63 | 2024 | Representative Director and Executive VP of Corporate Planning, Corp. Governance, HR & Accounting |
Yoshiharu Ikeda | 66 | 2020 | Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director |
Tsutomu Nakagawa | - | 2023 | Executive Officer, Chief Strategy Officer of Sumitomo Pharma America, Inc. & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review